Bio Protocol develops AI agents to enhance decentralized science operations

Bio Protocol is building what amounts to an AI workforce for decentralized science. The platform, which operates as a financial ecosystem for tokenized biotech research, has rolled out BioAgents and a comprehensive AI intelligence layer called Gaia, designed to let researchers and patients deploy decentralized AI co-scientists capable of generating hypotheses and coordinating scientific workflows.

What BioAgents actually do

The BioAgents platform tackles several pain points that have historically plagued scientific research coordination. Progress tracking, community engagement, and operational efficiency in DeSci projects all get an upgrade through agents that can analyze literature, support governance decisions, and coordinate communities.

These agents aren’t locked into any single infrastructure model. They can run on user hardware or cloud environments, utilizing frameworks such as Eliza and integrating with platforms like Discord and GitHub.

The Gaia layer, introduced by Elliot Brunet at the DeSci Berlin conference in June 2026, adds an accountability framework across six dimensions: Delivery, Transparency, Momentum, Stewardship, Legitimacy, and Impact. AI agents operating in scientific research need guardrails, and Gaia attempts to create a structured scoring system for whether those agents are actually producing useful work.

Complementing this is what Bio Protocol calls OpenLabs, spaces designed to foster human-agent collaboration in converting ideas into actionable funding proposals. The model emphasizes human-in-the-loop oversight alongside blockchain-verified outputs.

The money behind it

Bio Protocol raised $6.9 million in September 2025 specifically to build out its AI-native infrastructure. The round was led by Arthur Hayes’ Maelstrom and supported by Binance Labs/YZi Labs.

Projects operating within the Bio Protocol ecosystem have collectively raised over $33 million to date. That figure spans the platform’s evolution from Bio V1 in Q1 2025 through subsequent iterations, including the BioAgent Launchpad that went live in Q3 2025.

Strategic partnerships with VitaDAO and Molecule round out the ecosystem. VitaDAO has been one of the more prominent names in longevity research funding on-chain, and Molecule has carved out a niche as infrastructure for tokenized intellectual property in pharma.

The BIO token sits at the center of this economic machinery. It’s designed to incentivize the BioAgent fleet through staking for yields and governance, while also providing access to launchpads where new biotech projects can raise capital. In early 2026, the token experienced significant price surges tied to broader market enthusiasm around AI and DeSci narratives.